These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25565880)

  • 1. Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study.
    Roggeri DP; Cozzolino M; Mazzaferro S; Brancaccio D; Paoletti E; Roggeri A; Costanzo AM; di Luzio Paparatti U; Festa V; Messa P
    Int J Nephrol Renovasc Dis; 2015; 8():1-6. PubMed ID: 25565880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
    Roggeri DP; Mazzaferro S; Brancaccio D; Cannella G; Messa P; Di Luca M; Morosetti M; Costanzo AM; di Luzio Paparatti U; Cornago D; Cozzolino M;
    J Med Econ; 2012; 15(6):1110-7. PubMed ID: 22702445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
    Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
    J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Pharmacological Effects of Paricalcitol Versus Calcitriol on Secondary Hyperparathyroidism in the Dialysis Population.
    Večerić-Haler Ž; Romozi K; Antonič M; Benedik M; Ponikvar JB; Ponikvar R; Knap B
    Ther Apher Dial; 2016 Jun; 20(3):261-6. PubMed ID: 27312912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis.
    Zhang Z; Cai L; Wu H; Xu X; Fang W; He X; Wang X; Li X
    Front Public Health; 2021; 9():712027. PubMed ID: 34368073
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients.
    Kumar J; Tran NT; Schomberg J; Streja E; Kalantar-Zadeh K; Pahl M
    J Ren Nutr; 2016 Jul; 26(4):265-9. PubMed ID: 27038806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
    Llach F; Yudd M
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
    J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size.
    Vulpio C; Maresca G; Distasio E; Cacaci S; Panocchia N; Luciani G; Bossola M
    Hemodial Int; 2011 Jan; 15(1):69-78. PubMed ID: 21223484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
    Sprague SM; Llach F; Amdahl M; Taccetta C; Batlle D
    Kidney Int; 2003 Apr; 63(4):1483-90. PubMed ID: 12631365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget impact of secondary hyperparathyroidism treatment in chronic kidney disease in an Ecuadorian social security hospital.
    Manjarres L; Sanchez P; Cabezas MC; Fornasini M; Freire V; Albert A
    BMC Health Serv Res; 2016 Aug; 16(1):443. PubMed ID: 27566059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
    Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of paricalcitol versus calcitriol for the treatment of SHPT in dialytic patients from the SUS perspective.
    Menezes FG; Abreu RM; Itria A
    J Bras Nefrol; 2016; 38(3):313-319. PubMed ID: 27737389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study.
    Mittman N; Desiraju B; Meyer KB; Chattopadhyay J; Avram MM
    Kidney Int Suppl; 2010 Aug; (117):S33-6. PubMed ID: 20671742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential influence of vitamin D analogs on left ventricular mass index in maintenance hemodialysis patients.
    Sezer S; Tutal E; Bal Z; Uyar ME; Bal U; Cakir U; Acar NO; Haberal M
    Int J Artif Organs; 2014 Feb; 37(2):118-25. PubMed ID: 24619898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.
    Abdul Gafor AH; Saidin R; Loo CY; Mohd R; Zainudin S; Shah SA; Norella KC
    Nephrology (Carlton); 2009 Aug; 14(5):488-92. PubMed ID: 19298641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism.
    de Francisco AL; Gillespie IA; Gioni I; Floege J; Kronenberg F; Marcelli D; Wheeler DC; Froissart M; Drueke TB;
    Nefrologia; 2016; 36(2):164-75. PubMed ID: 26654696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
    Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.